GlassScriptPhysician profile
Leslie Stapp
NPI 1154380020
$57,874.60
in general payments reported to CMS, 2019-2025
23 companies · $1,931 in 2025
The $1,931 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,192 · 2021: $3,280 · 2022: $17K · 2023: $11K · 2024: $4,317 · 2025: $1,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $2,823 · Travel and Lodging: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,750.00 |
| Food and Beverage | $2,823.38 |
| Travel and Lodging | $1,309.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39,023.68 | 2020-2025 | Otezla, Otezla |
| Celgene Corporation | $7,867.31 | 2019 | |
| Pfizer INC. | $6,155.77 | 2019-2022 | |
| Abbvie INC. | $1,069.79 | 2019-2025 | Skyrizi |
| Biofrontera INC. | $755.13 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $552.15 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $404.75 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $369.44 | 2019-2025 | |
| Incyte Corporation | $267.54 | 2021-2025 | Opzelura |
| Ucb, INC. | $266.20 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $249.41 | 2019-2024 | |
| Lilly USA, LLC | $241.27 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.35 | 2019 | |
| Janssen Biotech, INC. | $141.71 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Epi Health, LLC | $103.42 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.35 | 2024-2025 | Spevigo |
| Chiesi USA, INC. | $45.86 | 2024 | Filsuvez |
| Galderma Laboratories, L.P. | $41.52 | 2019 | |
| Almirall LLC | $28.03 | 2019 | |
| Leo Pharma INC. | $24.20 | 2025 | Spevigo |
| Organogenesis INC. | $19.71 | 2023 | Puraply |
| Sun Pharmaceutical Industries INC. | $18.75 | 2021 | |
| Blueprint Medicines Corporation | $14.26 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Stapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.